SCHEDULE: RTW Investments Discloses 8.2% Stake in Replimune Group
Beneficial Ownership Report
RTW Investments, LP and Roderick Wong, M.D. have jointly filed a Schedule 13G, reporting beneficial ownership of 8.2% of Replimune Group, Inc.'s common stock.
Summary
- RTW Investments, LP and Roderick Wong, M.D. (collectively, 'Reporting Persons') have filed a Schedule 13G regarding their beneficial ownership in Replimune Group, Inc.
- The Reporting Persons beneficially own an aggregate of 6,395,732 shares of Replimune Group, Inc. common stock.
- This ownership represents 8.2% of the class, calculated based on 78,055,846 shares outstanding as of August 4, 2025.
- Both RTW Investments, LP and Roderick Wong, M.D. share voting and dispositive power over all 6,395,732 shares.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 7
Explanation: The disclosure of a significant institutional stake by a specialized healthcare investor like RTW Investments is generally viewed positively, indicating confidence in the company. The passive nature of the filing (ordinary course of business, not for control) also suggests a stable investment.
Positives
- A significant institutional investor, RTW Investments, LP, holds a substantial stake, potentially signaling confidence in Replimune Group, Inc.'s prospects.
- The filing explicitly states that the shares are held in the ordinary course of business, indicating a passive investment rather than an activist intent to influence control.
Negatives
- No direct negatives are presented in this beneficial ownership filing.
Risks
- No specific risks related to Replimune Group, Inc. are detailed in this beneficial ownership filing.
Future Outlook
NA
Industry Context
This filing indicates a significant investment by RTW Investments, a healthcare-focused investment firm, in Replimune Group, Inc., a biotechnology company. Such institutional stakes are common in the biotech sector, where specialized funds often take positions in companies with promising pipelines or technologies, signaling potential long-term confidence in the company's value proposition.
Stakeholder Impact
- Shareholders: May view the significant institutional investment as a vote of confidence, potentially stabilizing or positively influencing the share price.
- Management: Awareness of a large institutional holder may influence strategic decisions, though the filing states a passive investment intent.
Next Steps
- Reporting Persons will file amendments to this Schedule 13G if there are material changes to their beneficial ownership or investment intent.
Key Dates
| Date | Description |
|---|---|
| 2025-08-04 | Date Replimune Group, Inc. reported 78,055,846 shares outstanding in its Quarterly Report on Form 10-Q. |
| 2025-09-30 | Date of the event which required the filing of this statement. |
| 2025-11-14 | Date of signing the Joint Filing Agreement and the Schedule 13G. |
Keywords
Replimune Group Inc, RTW Investments, Roderick Wong, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology Investment, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.